Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 523-528

  Mohiuddin, Mohammed ^a   Paulus, Rebecca ^b   Mitchell, Edith ^c   Hanna, Nader ^d   Yuen, Albert ^e   Nichols, Romaine ^f   Yalavarthi, Salochna ^g   Hayostek, Cherie ^h   Willett, Christopher ⁱ  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b RTOG Statistical Center   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e READING HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g Ingalls Memorial Hospital   (United States)

^h Santa Fe Radiology   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY; PATIENT TREATMENT; RADIOTHERAPY; SURGERY;

5-FLUOROURACIL (5-FU); DISEASE PROGRESSION; DISEASE-SPECIFIC SURVIVAL RATES; INDUCTION CHEMOTHERAPY; LOCOREGIONAL RECURRENCE; METHODS AND MATERIALS; NEOADJUVANT CHEMORADIATION; OVERALL SURVIVAL RATES;

DISEASES;

FLUOROURACIL; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTAL RECTUM CANCER; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; TREATMENT REFUSAL; ADJUVANT THERAPY; ALGORITHM; CHEMORADIOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MORTALITY; PATHOLOGY; RADIATION DOSE; RECTUM TUMOR; SURVIVAL RATE; TREATMENT FAILURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880618451     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.020     Document Type: Article

References (19)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemotherapy for rectal cancer. N Engl J Med 2004;351: 1731-1740.
2. Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-614.
3. Bosset JF, Calais G, Mineur L, et al. Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: Report of the 22921 EORTC phase III trial. J Clin Oncol 2004;23:247.
4. Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for Pathological complete response. Int J Radiat Oncol Biol Phys 2000;46:883-888.
5. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006;24:650-655.
6. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Amr Stat Assoc 1958;53:457-481.
7. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
8. O'Connell MJ, Martenson JA, Wieand HS, et al. Improved combined modality surgical adjuvant therapy for high-risk rectal cancer. N Engl J Med 1994;331:502-507.
9. Roedel C, Becker H, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-flourouracil and oxaliplatin versus 5-flourouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized Phase III trial. J Clin Oncol 2011;29(Suppl):222s [abstract LBA3505].
10. Wong SJ, Moughan J, Meropol NJ, et al. Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer. J Clin Oncol 2011; 29(suppl) [abstract 3517].
11. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-1644.
12. Aschele C, Cionini L, Loardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773-2780.
13. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-5130.
14. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29(Suppl) [abstract 3503].
15. Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000;48:1075-1080.
16. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-8696.
17. Mass M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of 3105 patients. Lancet Oncol 2010; 11:835-844.
18. Mitchell EP. Irinotecan in preoperative combined modality therapy for locally advanced rectal cancer. Oncology 2000;14:56-59.
19. Wong SJ, Winter K, Meropol NJ, et al. RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. J Clin Oncol 2008;26(Suppl):1367-1375 [abstract 4021].